ABVC BIOPHARMA

Company snapshot

ABVC BioPharma (NASDAQ:ABVC), a biopharma and medical device company developing therapies for a range of conditions focused on oncology/hematology, central nervous system (CNS) and ophthalmology, has several potential paths to achieving near-term milestones as it advances its portfolio of novel medical products.

• 1 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for ABVC BIOPHARMA. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for ABVC BIOPHARMA.

1. Jun 5, 2026 Clinical update

   PDC-1421 Capsule — Phase 2

View all clinical trial activity →

• What is ABVC BIOPHARMA?

  ABVC BioPharma is a biotech organization headquartered in Fremont, USA. It trades on NYSE under ticker ABVC. Primary therapeutic focus areas include Attention-Deficit Hyperactivity Disorder (ADHD). NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record

• Is ABVC BIOPHARMA publicly traded?

  Yes. ABVC BIOPHARMA is listed with ticker ABVC on NYSE per SEC EDGAR records linked on this profile.

• What drugs does ABVC BIOPHARMA develop or market?

  We link 1 drug profile(s) where ABVC BIOPHARMA is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/abvc-biopharma-inc#company-drugs.

• What are the latest developments for ABVC BIOPHARMA?

  In the last 12 months our linked public records show 1 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does ABVC BIOPHARMA focus on?

  ABVC BIOPHARMA focuses on Attention-Deficit Hyperactivity Disorder (ADHD) based on our analysis of their pipeline programs and drug development activities.